Iovance Biotherapeutics Inc (NAS:IOVA)
$ 9.32 -0.08 (-0.85%) Market Cap: 2.84 Bil Enterprise Value: 2.52 Bil PE Ratio: 0 PB Ratio: 3.67 GF Score: 39/100

Iovance Biotherapeutics Inc at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript

Apr 24, 2023 / 05:00PM GMT
Release Date Price: $5.7 (-0.18%)
Geulah Livshits
Chardan - Analyst

Hello, it's now my pleasure to introduce Dr. Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics. The format for this session is roughly a 25-minute fireside chat, and if you have any questions in the session, feel free to type them into the question box and we'll try to ask them on your behalf. Igor, Iovance recently completed its BLA submission for the salicylic melanoma, which was an important step for the company.

Maybe to start off, can you give us a brief overview of Iovance' [skilled] programs and the company's strategic approach to manufacturing, and then we'll dive into the details a little bit more. Great to have you.

Igor Bilinsky
Iovance Biotherapeutics, Inc. - COO

Happy to. Thank you, Gorilla. Good afternoon, Gorilla. Good afternoon, everyone. Great to be here. Iovance --

Actually, I'll start with forward-looking statements. We're a publicly listed company. I'll be making forward-looking statements as part of this discussion. I refer you to our filings with the SEC for a full

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot